- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02569606
Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
Study Overview
Status
Conditions
Detailed Description
Trauma is one of the leading causes of death worldwide. After death due to direct craniofacial injury, exsanguination is the next major cause for trauma mortality.
After initial pre-hospital treatment the patient is admitted to the hospital. If multiple injuries are present the patient is transferred to a specialized trauma center.
Besides surgical treatment, the patient needs stabilization of the vital functions by the Anesthesiologist. Due to loss of blood volume, dilution of the circulatory blood volume and pathological activation of coagulation/fibrinolysis, trauma induced coagulopathy (TIC) is initiated. This needs to be treated and avoided whenever possible.
Transfusion of allogeneic blood and coagulation product itself leads to an increased morbidity and mortality. Infectious and immunologic reactions account for that phenomenon.
This led to a paradigm change in the therapy of TIC. In 2009 a new coagulation factor based coagulation algorithm was introduced in the Hospital Lucerne and the University Hospital in Zurich / Switzerland. With the help of point of care coagulation measurement, tailored coagulation factor based coagulation management and avoidance of allogeneic blood products was initiated.
The investigators now want to analyze the impact of the coagulation algorithm by comparing the periods before and after the introduction of the algorithm.
The consumption of blood and coagulation products (packed red blood cells, fresh frozen plasma, platelet concentrates, fibrinogen, coagulation factor concentrates, coagulation factor XIII, activated factor VII, van Willebrand factor and antifibrinolytics) before and after the introduction of a designated trauma related transfusion and coagulation algorithm will be recorded and compared. The periods 2005-2007 (before) and 2012-2014 (after) the introduction are reviewed. Predicted probability of a massive transfusion by the TASH score (trauma associated acute hemorrhage) is correlated with the actual rate.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lucerne, Switzerland, 6000
- Lucerne Kantonssital
-
Zurich, Switzerland, 8091
- University Hospital Zürich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- male and female trauma patients
- admitted to the University hospital of Zurich or the Hospital of Lucerne, Switzerland
- injury severity score >= 16
- time period 2005-2007 and 2012-2014
Exclusion Criteria:
- incomplete data
- denial of informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Timeframe 2005 - 2007
Data of timeframe 2005 up to 2007 will be included
|
|
Timeframe 2012 - 2014
Data of timeframe 2012 up to 2014 will be included
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison the consumption of red blood cells, fresh frozen plasma and platelets in the treatment period by the Anaesthesist and after 24/48 hours before (2005-2007) and after (2012-2014) launching the coagulation algorithm.
Time Frame: up to 48 hours
|
The coagulation algorithm was launched in 2010.
To show the difference in transfusion and administration of coagulation products prior and after the changes of coagulation algorithm the probability of massive transfusion (TASH Score) will be compared with the actual rate.
The TASH Score is the most precise predictive probability of a massive transfusion.
Data of approximately 1800 participants will be compared.
|
up to 48 hours
|
|
Comparison of the rate of massive transfusion in reality with the predicted rate (by TASH) score.
Time Frame: up to 48 hours
|
Massive transfusion (>10 units of blood) can be predicted on the base of patient and trauma epidemiology.
The investigator compares the actual rate in the institution with the rate predicted by the score.
|
up to 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of the predicted mortality (TRISS/RISC2) with the actual rate
Time Frame: up to 30 days
|
TRISS is a common Score and is a comparative value for trauma mortality outcome.
The investigators want to show the benefit of launched coagulation algorithm in mortality after severe trauma.
|
up to 30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZH 2015 - 0309
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhage
-
Region StockholmRecruitingRetinal Hemorrhage, Bilateral | Retinal Hemorrhage, Left Eye | Retinal Hemorrhage, Right EyeSweden
-
Al Hadi HospitalCompletedDiabetic Vitreous HemorrhageKuwait
-
Massachusetts Eye and Ear InfirmaryCompletedPost-operative HemorrhageUnited States
-
Panhandle Eye Group, LLPRecruitingDiabetic Vitreous HemorrhageMexico
-
Weill Medical College of Cornell UniversityThe Edward Grayson Fund for Retinal ResearchUnknownSubretinal Hemorrhage and Exudative MaculopathyUnited States
-
Tel-Aviv Sourasky Medical CenterMedical Corps, Israel Defense ForceActive, not recruiting
-
Ain Shams Maternity HospitalUnknownPost Operative HemorrhageEgypt
-
Asan Medical CenterUnknownPost Vitrectomy State | Recurrent Diabetic Vitreous HemorrhageKorea, Republic of
-
University of Sao PauloUnknownHemorrhage | RecurrentBrazil
-
CytoSorbents, IncCompletedBlood Loss, Surgical | Blood Loss, Postoperative | Hemorrhage, Surgical | Hemorrhage PostoperativeUnited States, Canada